Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Article
in En
| MEDLINE
| ID: mdl-37363833
Full text:
1
Database:
MEDLINE
Main subject:
Leukemia, Lymphocytic, Chronic, B-Cell
Type of study:
Diagnostic_studies
/
Prognostic_studies
/
Qualitative_research
Limits:
Aged
/
Humans
Language:
En
Journal:
Blood
Year:
2023
Type:
Article
Affiliation country:
Netherlands